Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC

Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC

Introduction: There are no standard targeted treatment options for advanced KRAS-mutant NSCLC beyond KRAS G12C inhibitors. A computational model identified regorafenib and low-dose methotrexate as synergistic in preclinical models of KRAS-mutant NSCLC. This study evaluated the efficacy and safety of...

Full description

Saved in:
Bibliographic Details
Main Authors: Jacqueline V. Aredo, MD, MS, Heather A. Wakelee, MD, Kavitha J. Ramchandran, MD, Joel W. Neal, MD, PhD, Maximilian Diehn, MD, PhD, Angela Bik-Yu Hui, PhD, Ameen Salahudeen, MD, PhD, Bernice Kwong, MD, Gerald J. Berry, MD, H. Henry Guo, MD, PhD, Kristen Cunanan, PhD, Shireen Vali, PhD, Danny Pancirer, BA, Vivian Tsang, MSN, Grace Hwang, MS, Monica Loza, BA, Brittany Johnson, BA, Isabelle Blanchard, BS, Sukhmani K. Padda, MD
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:JTO Clinical and Research Reports
Subjects:
KRAS mutation
Regorafenib
Methotrexate
Targeted therapy
ctDNA
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001115
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324001115

Similar Items